Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an eye to com­plet­ing Phase I/II de­vel­op­ment for its lead cell ther­a­py pro­gram in two dif­fer­ent in­di­ca­tions, End­points News has learned.

The Se­ries A should be com­plet­ed in ear­ly 2024, CEO Karine Rossig­nol told End­points on the side­lines of the Jef­feries health­care meet­ing Tues­day. “We need to have a mix of Eu­ro­pean in­vestors, US in­vestors and ide­al­ly phar­ma in­vestors,” Rossig­nol said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER